摘要
目的探讨糖类抗原125（CA125）及溶血磷脂酸（LPA）联合测定对早期卵巢癌的诊断价值。方法对76例卵巢癌患者（卵巢癌组），35例卵巢良性肿瘤患者（良性肿瘤组）及29例健康志愿者（健康组），分别测定其血清CA125及LPA的含量，并对其联合测定与单项测定进行比较。结果卵巢癌组、良性肿瘤组、健康志愿者的CA125为（353．7±139．6）RU／L、（38．8±16．1）RU／L、（20．1±14．9）RU／L;LPA分别为（9．23±2．19）μmol／L、（2．34±0．95）μmol／L、（2．10±0．77）μmol／L。卵巢癌组与良性肿瘤组和健康对照组相比，两项标志物的血清含量差异均有统计学意义（P〈0．05），但良性肿瘤组与健康对照组之间差异无统计学意义（P〉0．05）。结论提示血清CA125与IPA联合测定对卵巢癌的早期诊断具有一定价值。
Objective To investigate clinical value of levels of CA125 and LPA as a panel for early diagnosis of ovarian cancer. Methods The levels of two tumor markers（ CA125 and LPA） in serum were determined in 76 patients with ovarian cancer,35 patients with benign tumor and 29 healthy control. Results The results showed that the levels of two tumor markers in ovarian cancer patients were significantly higher than those in benign tumor patients and controls （ P 〈 0. 05 ）. Butuo significant difforences was foud betwcen benigutumor patient and coatrols. Conclusion Combined detection of the two markers represent a potential biomarker for diagnosis of epithelial ovarian cancer because of its diagnostic accuracy in ovarian cancer case.
出处
《中国基层医药》
CAS
2009年第11期1993-1994,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
卵巢肿瘤
抗原
Ovarian Neoplasms
Antigens
